Your browser is no longer supported. Please, upgrade your browser.
Settings
OCX [AMEX]
OncoCyte Corporation
Index- P/E- EPS (ttm)-0.51 Insider Own0.80% Shs Outstand67.25M Perf Week-8.01%
Market Cap494.58M Forward P/E- EPS next Y-0.35 Insider Trans304.24% Shs Float36.33M Perf Month0.17%
Income-31.60M PEG- EPS next Q-0.11 Inst Own40.10% Short Float5.23% Perf Quarter220.22%
Sales0.70M P/S706.55 EPS this Y-5.00% Inst Trans5.29% Short Ratio0.77 Perf Half Y318.57%
Book/sh0.52 P/B11.27 EPS next Y27.10% ROA-57.30% Target Price6.14 Perf Year127.13%
Cash/sh0.13 P/C46.22 EPS next 5Y- ROE-89.10% 52W Range1.15 - 6.57 Perf YTD145.19%
Dividend- P/FCF- EPS past 5Y-17.40% ROI- 52W High-18.72% Beta1.99
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin-59.50% 52W Low364.35% ATR0.68
Employees33 Current Ratio1.30 Sales Q/Q- Oper. Margin- RSI (14)50.36 Volatility12.04% 13.01%
OptionableYes Debt/Eq0.13 EPS Q/Q-0.30% Profit Margin- Rel Volume0.32 Prev Close5.86
ShortableYes LT Debt/Eq0.07 Earnings- Payout- Avg Volume2.47M Price5.34
Recom2.00 SMA20-6.64% SMA5029.37% SMA200122.29% Volume792,201 Change-8.87%
Jan-07-21Upgrade The Benchmark Company Speculative Buy → Buy $6
Dec-16-20Upgrade Piper Sandler Neutral → Overweight $2 → $4
Nov-30-20Initiated BTIG Research Buy $5
Nov-10-20Initiated KeyBanc Capital Markets Overweight $5
Jul-30-20Reiterated The Benchmark Company Speculative Buy $7 → $6
Jul-01-20Downgrade Piper Sandler Overweight → Neutral
Jun-30-20Downgrade Chardan Capital Markets Buy → Neutral $2
Jun-02-20Initiated Needham Buy $4
Feb-13-19Initiated Piper Jaffray Overweight $6
Jan-29-19Upgrade Janney Neutral → Buy
Dec-19-18Resumed Lake Street Buy
Feb-25-21 08:00AM  
Feb-23-21 04:05PM  
Feb-16-21 04:05PM  
01:24AM  
Feb-09-21 04:05PM  
Feb-05-21 06:06PM  
08:25AM  
Feb-04-21 04:05PM  
Feb-02-21 09:35AM  
08:00AM  
Jan-29-21 08:30PM  
Jan-28-21 08:00AM  
Jan-20-21 04:08PM  
Jan-12-21 06:21PM  
Dec-17-20 08:50AM  
Dec-15-20 10:48AM  
09:46AM  
08:18AM  
08:10AM  
08:00AM  
01:33AM  
Dec-07-20 04:05PM  
Nov-30-20 05:38PM  
Nov-18-20 04:05PM  
08:00AM  
Nov-17-20 11:55PM  
Nov-16-20 05:49AM  
Nov-12-20 04:05PM  
02:30PM  
Nov-09-20 04:05PM  
Nov-05-20 11:23AM  
Nov-02-20 08:00AM  
Oct-28-20 08:00AM  
Oct-20-20 05:21PM  
Oct-14-20 08:00AM  
Oct-08-20 08:00AM  
Oct-01-20 08:00AM  
Sep-15-20 07:59AM  
Sep-14-20 08:00AM  
Sep-09-20 08:00AM  
Sep-03-20 08:00AM  
Sep-01-20 11:00AM  
Aug-27-20 08:00AM  
Aug-13-20 04:05PM  
Aug-11-20 08:00AM  
Aug-07-20 08:49AM  
Jul-29-20 06:45PM  
04:05PM  
Jul-20-20 04:05PM  
08:00AM  
Jul-16-20 08:00AM  
Jul-14-20 08:00AM  
Jul-02-20 10:54AM  
Jun-30-20 07:41AM  
Jun-29-20 04:05PM  
Jun-17-20 10:32AM  
Jun-15-20 08:00AM  
Jun-10-20 04:18PM  
May-13-20 05:51PM  
May-12-20 04:05PM  
May-05-20 08:00AM  
08:00AM  
May-01-20 08:00AM  
Apr-30-20 02:21PM  
Apr-24-20 08:00AM  
Apr-23-20 08:00AM  
Apr-15-20 10:55PM  
Apr-07-20 03:35PM  
09:00AM  
08:00AM  
Mar-25-20 04:05PM  
02:30PM  
Mar-19-20 08:00AM  
Mar-18-20 08:00AM  
Feb-05-20 08:00AM  
Jan-30-20 08:00AM  
Jan-13-20 08:00AM  
Jan-10-20 04:05PM  
Jan-07-20 08:00AM  
Jan-02-20 08:08PM  
Dec-23-19 02:19PM  
Dec-09-19 11:42AM  
Nov-27-19 08:00AM  
Nov-14-19 04:05PM  
Nov-11-19 12:15PM  
Nov-08-19 08:00AM  
Oct-31-19 08:00AM  
Oct-15-19 08:00AM  
Oct-09-19 08:12AM  
Oct-01-19 08:00AM  
Sep-19-19 10:09AM  
Sep-05-19 08:00AM  
Aug-14-19 04:05PM  
Jul-31-19 08:00AM  
Jul-26-19 05:08PM  
Jul-24-19 08:00AM  
Jul-11-19 03:30PM  
11:28AM  
Jul-09-19 05:08PM  
Jul-07-19 05:33PM  
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROADWOOD PARTNERS, L.P.10% OwnerFeb 05Buy4.50600,0002,700,00016,776,484Feb 09 05:21 PM
BROADWOOD PARTNERS, L.P.10% OwnerJan 20Buy3.421,460,2804,999,99916,176,484Jan 22 04:28 PM
KINGSLEY ALFRED DDirectorDec 28Option Exercise1.3465,27187,463384,111Dec 28 09:46 PM
KINGSLEY ALFRED DDirectorDec 23Option Exercise1.341,2371,658319,740Dec 28 09:46 PM
KINGSLEY ALFRED DDirectorDec 23Sale2.559002,295318,840Dec 28 09:46 PM
KINGSLEY ALFRED DDirectorDec 22Option Exercise1.3410,51614,091326,155Dec 23 09:12 PM
KINGSLEY ALFRED DDirectorDec 21Option Exercise1.3447,97664,288350,787Dec 23 09:12 PM
KINGSLEY ALFRED DDirectorDec 21Sale2.545,14813,076315,639Dec 23 09:12 PM
ANDREWS RONALD ASBURYChief Executive OfficerAug 03Buy1.3540,00053,880102,698Aug 04 06:50 PM
Levine Mitchell SChief Financial OfficerAug 03Buy1.3210,00013,20036,579Aug 04 06:47 PM
Parker Albert PChief Operating OfficerAug 03Buy1.335,0006,6485,000Aug 05 07:36 PM
KALAJIAN TONY TSr.VP/Chief Accounting OfficerAug 03Buy1.315,0006,53315,000Aug 05 07:34 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 24Buy2.271,050,0002,383,50014,716,204Apr 28 06:14 PM
ANDREWS RONALD ASBURYCEO and PresidentMar 31Buy2372.0018,00042,696,00062,698Apr 01 04:05 PM
ANDREWS RONALD ASBURYCEO and PresidentMar 30Buy2.2627,21661,45444,698Apr 01 04:05 PM
Levine Mitchell SChief Financial OfficerMar 14Option Exercise0.0020,000033,495Apr 20 04:42 PM